NICE drafts a 'no' to Zaltrap
This article was originally published in Scrip
Executive Summary
NICE, the healthcare guidance body for England and Wales, has issued new draft guidance that does not recommend aflibercept (Sanofi's Zaltrap) for treating metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing regimen.